Pierre Fabre Médicament SAS (Pierre Fabre) to register and commercialize vibegron for the treatment of Overactive Bladder (OAB) in the Europe Economic Area, UK, and Switzerland. Urovant Sciences
New analyses of data from the Phase 3 EMPOWUR Extension Study of GEMTESA (vibegron) 75 mg provided additional insight into the long-term effects of the product. These data were featured in podium
Interim 12-week analysis from an ongoing Phase 2a trial of an investigational novel gene therapy product (plasmid human cDNA encoding maxi-K channel) showed clinically relevant improvement in the
Post-hoc analysis indicates significant reductions in urgency episodes and micturitions in patients treated with GEMTESA vs. placebo in both types of overactive bladder (OAB) Article appears
Review article in a peer-reviewed journal examines studies of GEMTESA published in the past 3 years Data support GEMTESA's role as an effective treatment option for overactive bladder (OAB)